National Heart, Lung, and Blood Institute; Notice of Meeting, 76207 [2022-26996]
Download as PDF
<![CDATA[
Federal Register / Vol. 87, No. 238 / Tuesday, December 13, 2022 / Notices
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Advancing Translational Sciences Advisory
Council.
Date: January 26, 2023.
Closed: 11:00 a.m. to 12:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Center for Advancing
Translational Sciences, National Institutes of
Health, One Democracy Plaza 9th Floor,
Room 987/989, 6701 Democracy Boulevard,
Bethesda, MD 20892 (Virtual Meeting).
Open: 1:00 p.m. to 6:00 p.m.
Agenda: Report from the Institute Director,
Invited Speaker presentation, Office of
Special Initiates (OSI) and Office of Strategic
Alliances (OSA) Program Updates.
Place: National Center for Advancing
Translational Sciences, National Institutes of
Health, One Democracy Plaza, 9th Floor,
Room 987/989, 6701 Democracy Boulevard,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Anna L. Ramsey-Ewing,
Ph.D., Executive Secretary, National Center
for Advancing Translational Sciences, 1
Democracy Plaza, Room 1072, Bethesda, MD
20892, 301–435–0809, anna.ramseyewing@
nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice no later than 15 days after the
meeting at NCATSCouncilInput@
mail.nih.gov. The statement should include
the name, address, telephone number and
when applicable, the business or professional
affiliation of the interested person.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.350, B—Cooperative
Agreements; 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
Dated: December 7, 2022.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–26992 Filed 12–12–22; 8:45 am]
BILLING CODE 4140–01–P
lotter on DSK11XQN23PROD with NOTICES1
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
VerDate Sep<11>2014
17:48 Dec 12, 2022
Jkt 259001
76207
meeting of the Sickle Cell Disease
Advisory Committee.
The meeting will be open to the
public through a virtual meeting.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Name of Committee: Sickle Cell Disease
Advisory Committee.
Date: January 30, 2023.
Time: 10:00 a.m. to 2:30 p.m.
Agenda: Research, engagement and
representation from the community.
Place: National Institutes of Health,
Rockledge 1, 6705 Rockledge Dr, Bethesda,
MD 20892, (Virtual Meeting—Teleconference
andZoomGov).
Telephone Access: +1 669 254 5252
(Meeting ID 160 763 2658).
Virtual Access: https://nih.zoomgov.com/j/
1607632658, (Meeting ID: 160 763 2658).
Contact Person: Nahed El Kassar, MD,
Ph.D. Medical Officer National Heart, Lung,
and Blood Institute, Blood Epidemiology &
Clinical Therapeutics Branch, Division of
Blood Diseases and Resources, 6701
Rockledge Drive, Suite 9166, Bethesda, MD
20892, 301–435–0080,
NHLBIDBDRGrantResource@nhlbi.nih.gov.
Any member of the public interested in
presenting oral comments to the committee
may notify the Contact Person listed on this
notice at least 10 days in advance of the
meeting. Interested individuals and
representatives of organizations may submit
a letter of intent, a brief description of the
organization represented, and a short
description of the oral presentation. Only one
representative of an organization may be
allowed to present oral comments and if
accepted by the committee, presentations
may be limited to five minutes. Both printed
and electronic copies are requested for the
record. In addition, any interested person
may file written comments with the
committee by forwarding their statement to
the Contact Person listed on this notice. The
statement should include the name, address,
telephone number and when applicable, the
business or professional affiliation of the
interested person.
Information is also available on the
Institute’s/Center’s home page:
www.nhlbi.nih.gov/meetings/index.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
HHS.
Dated: December 8, 2022.
David W Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–26996 Filed 12–12–22; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
National Institutes of Health
Request for Information (RFI) on
Proposed Simplified Review
Framework for NIH Research Project
Grant Applications; Correction
AGENCY:
National Institutes of Health,
Request for information;
correction.
ACTION:
The Department of Health and
Human Services, National Institutes of
Health published a Notice in the
Federal Register on December 7, 2022.
That Notice requires a correction in the
SUPPLEMENTARY INFORMATION section.
FOR FURTHER INFORMATION CONTACT:
Questions about this request for
information should be directed to Office
of Extramural Research, Dr. Kristin
Kramer, Phone number (301) 437–0911,
Email simplifiedreview@nih.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
Correction
In the Federal Register of December 7,
2022 in FR Doc. 2022–26603, on pages
75056–75057, as found within the
SUPPLEMENTARY INFORMATION section,
which provides reference URLs to the
following:
Proposal Development
March 2021 slides; currently reads
https://public.csr.nih.gov/sites//files/
2021-04/Simplifying_Review_Criteria_
29_March_2021.pdf and is corrected to
read https://public.csr.nih.gov/sites/
default/files/2021-04/Simplifying_
Review_Criteria_29_March_2021.pdf.
Final recommendations from the CSR
Advisory Council report; currently reads
https://public.csr.nih.gov/sitest/files/
2021-04/Recommendations_of_the_
CSRAC_Working_Group_on_
Simplifying_Review-non-CT_and_
CT.pdf and is corrected to read https://
public.csr.nih.gov/sites/default/files/
2021-04/Recommendations_of_the_
CSRAC_Working_Group_on_
Simplifying_Review-non-CT_and_
CT.pdf.
Additional background information
can be found here; currently reads
https://grants.nih.gov/policyroposedFramework/index.htm and is corrected
to read https://grants.nih.gov/policy/
peer/Proposed-Framework/index.htm
Proposed Revised Simplified Review
Framework
Detailed descriptions of the three
factors can be found here; currently
reads https://grants.nih.gov/
E:\FR\FM\13DEN1.SGM
13DEN1
]]>Agencies
[Federal Register Volume 87, Number 238 (Tuesday, December 13, 2022)]
[Notices]
[Page 76207]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-26996]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Meeting
Pursuant to section 10(a) of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the Sickle Cell Disease
Advisory Committee.
The meeting will be open to the public through a virtual meeting.
Individuals who plan to attend and need special assistance, such as
sign language interpretation or other reasonable accommodations, should
notify the Contact Person listed below in advance of the meeting.
Name of Committee: Sickle Cell Disease Advisory Committee.
Date: January 30, 2023.
Time: 10:00 a.m. to 2:30 p.m.
Agenda: Research, engagement and representation from the
community.
Place: National Institutes of Health, Rockledge 1, 6705
Rockledge Dr, Bethesda, MD 20892, (Virtual Meeting--Teleconference
andZoomGov).
Telephone Access: +1 669 254 5252 (Meeting ID 160 763 2658).
Virtual Access: https://nih.zoomgov.com/j/1607632658, (Meeting
ID: 160 763 2658).
Contact Person: Nahed El Kassar, MD, Ph.D. Medical Officer
National Heart, Lung, and Blood Institute, Blood Epidemiology &
Clinical Therapeutics Branch, Division of Blood Diseases and
Resources, 6701 Rockledge Drive, Suite 9166, Bethesda, MD 20892,
301-435-0080, [email protected].
Any member of the public interested in presenting oral comments
to the committee may notify the Contact Person listed on this notice
at least 10 days in advance of the meeting. Interested individuals
and representatives of organizations may submit a letter of intent,
a brief description of the organization represented, and a short
description of the oral presentation. Only one representative of an
organization may be allowed to present oral comments and if accepted
by the committee, presentations may be limited to five minutes. Both
printed and electronic copies are requested for the record. In
addition, any interested person may file written comments with the
committee by forwarding their statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
Information is also available on the Institute's/Center's home
page: www.nhlbi.nih.gov/meetings/index.htm, where an agenda and any
additional information for the meeting will be posted when
available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.233,
National Center for Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839,
Blood Diseases and Resources Research, National Institutes of
Health, HHS)
Dated: December 8, 2022.
David W Freeman,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-26996 Filed 12-12-22; 8:45 am]
BILLING CODE 4140-01-P
